This spin-off, one of the runners-up for the BioEmprenedorXXI award, is developing a new therapy to treat sepsis. 25% of patients in ICUs develop this infection.
The operation, which will allow Sciclone to use technology developed by Intelligent Pharma to better understand how specific molecules work, will help drivethe Catalan biotechnology company’s international expansion.
Catalan Telstar and British Puretech Process Systems have been strategic partners since the end of last year. Jordi Net, Telstar Sales Marketing Director says, “The new brand is synonymous with high quality and lower life-cycle prices.”
